
On Friday, biotech firm Oprhazyme has been moved to Nasdaq Copenhagen’s observation list.
The request came shortly after Oprhazyme sought protection from creditors, which would allow time for an in-court restructuring of the company, Nasdaq reports.
Already a subscriber? Log in.
Read the whole article
Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
- Access all locked articles
- Receive our daily newsletters
- Access our app